Arbutus Moderna RNAi LNP IP Patent COVID-19

Is Moderna’s LNP Technology a Patent Infringement against Arbutus

According to Mark Murry (CEO of Arbutus), “We have seen no evidence of a Moderna delivery system that is free of our intellectual property. Not in their publications, their presentations, or in the examples in their patent filings.” Read more about this in a Forbes article: Moderna Can’t Escape My Intellectual Property, Says Arbutus CEO …

Is Moderna’s LNP Technology a Patent Infringement against Arbutus Read More »